AQR reports 6.22% stake in Aldeyra Therapeutics
AQR Capital Management, LLC and its parent AQR Capital Management Holdings, LLC report beneficial ownership of Aldeyra Therapeutics, Inc. common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
AQR Capital Management, LLC and its parent AQR Capital Management Holdings, LLC report beneficial ownership of Aldeyra Therapeutics, Inc. common stock. They state beneficial ownership of 3,751,558 shares of common stock, representing 6.22% of the outstanding class.
Both entities report shared voting power over 3,381,606 shares and shared dispositive power over 3,751,558 shares, with no sole voting or dispositive power. AQR Capital Management, LLC is described as a wholly owned subsidiary of AQR Capital Management Holdings, LLC.
Key Figures
Key Terms
beneficially owned financial
dispositive power financial
parent holding company financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Aldeyra Therapeutics (ALDX) does AQR Capital report owning?
What dispositive power does AQR Capital report for its Aldeyra Therapeutics (ALDX) holdings?
Where is Aldeyra Therapeutics (ALDX) headquartered according to this ownership report?
AI-generated analysis. How Rhea-AI works. Not financial advice.